glp-1 therapies UC Davis Health examines systemic impact of GLP-1–based GLP-1 Therapies May Benefit MPN
Description
2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD
What are GLP-1 Drugs
May 18, 2026/Heart, Vascular and Thoracic/Heart Failure & Transplant GLP-1 RAs Show Survival and Cardiovascular Benefits in Patients With HFrEF and Diabetes Large retrospective analysis may prompt prospective studies April 30, 2026/Ob/Gyn & Womens Health/Maternal-Fetal Medicine Preconception GLP-1 Use Not Linked to Higher Pregnancy Risk Data point to potential for targeted preconception planning April 10, 2026/Heart, Vascular and Thoracic/Vascular Medicine New Data Suggest GLP-1 Receptor Agonists Slow Abdominal Aortic Aneurysm Progression Robust signal from observational study raises prospect of a long-sought medical therapy March 30, 2026/Heart, Vascular and Thoracic/Preventive Cardiology Dual-Agonist Incretin Therapy Outshines GLP-1 Agonist in Broad Cardiorenal Outcomes Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials Advertisement Cleveland Clinic is a non-profit academic medical center
Ampk agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice
doi: 10.1038/nutd.2016.15
